Skip to main navigation Skip to search Skip to main content

Non-nuclear WldS determines its neuroprotective efficacy for axons and synapses in vivo

  • Bogdan Beirowski
  • , Elisabetta Babetto
  • , Jon Gilley
  • , Francesca Mazzola
  • , Laura Conforti
  • , Lucie Janeckova
  • , Giulio Magni
  • , Richard R. Ribchester
  • , Michael P. Coleman
  • Babraham Institute
  • Marche Polytechnic University
  • University of Edinburgh

Research output: Contribution to journalArticlepeer-review

90 Scopus citations

Abstract

Axon degeneration contributes widely to neurodegenerative disease but its regulation is poorly understood. The Wallerian degeneration slow (Wld S) protein protects axons dose-dependently in many circumstances but is paradoxically abundant in nuclei. To test the hypothesis that WldS acts within nuclei in vivo, we redistributed it from nucleus to cytoplasm in transgenic mice. Surprisingly, instead of weakening the phenotype as expected, extranuclear WldS significantly enhanced structural and functional preservation of transected distal axons and their synapses. In contrast to native WldS mutants, distal axon stumps remained continuous and ultrastructurally intact up to 7 weeks after injury and motor nerve terminals were robustly preserved even in older mice, remaining functional for 6 d. Moreover, we detect extranuclear WldS for the first time in vivo, and higher axoplasmic levels in transgenic mice with WldS redistribution. Cytoplasmic WldS fractionated predominantly with mitochondria and microsomes. We conclude that WldS can act in one or more nonnuclear compartments to protect axons and synapses, and that molecular changes can enhance its therapeutic potential.

Original languageEnglish
Pages (from-to)653-668
Number of pages16
JournalJournal of Neuroscience
Volume29
Issue number3
DOIs
StatePublished - Jan 21 2009

Keywords

  • Axon degeneration
  • Neurodegeneration
  • Neuromuscular junction
  • Neuroprotection
  • Slow Wallerian degeneration gene
  • Wallerian degeneration

Fingerprint

Dive into the research topics of 'Non-nuclear WldS determines its neuroprotective efficacy for axons and synapses in vivo'. Together they form a unique fingerprint.

Cite this